Top

International Journal of Colorectal Disease

Published in:

01-06-2014 | Original Article

Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

Authors: Mathilde Feist, Xiaohua Huang, Joachim M. Müller, Beate Rau, Wolfgang Dubiel

Published in: International Journal of Colorectal Disease | Issue 6/2014

Abstract

Purpose

A frequently used chemotherapeutic agent in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitomycin C (MMC) which induces DNA damage and apoptosis in tumor cells. In addition, MMC activates DNA damage response (DDR) leading to repair mechanisms counteracting the effect of chemotherapy. COP9 signalosome (CSN) positively influences the DDR pathway by its intrinsic deneddylating and associated kinase activities. In an in vitro HIPEC model, we studied the impact of curcumin, an inhibitor of CSN-associated kinases, and of the microRNA (miRNA) let-7a-1, an inhibitor of CSN subunit expression, on the MMC-induced apoptosis in human HT29 colon cancer cells.

Methods

Cells were incubated at 37 °C and indicated concentrations of MMC in a medium preheated to 42 °C as under HIPEC conditions for 1 or 4 h. HT29 cells were cotreated with 50 μM curcumin or transfected with let-7a-1 miRNA mimic. After incubation, cells were analyzed by Western blotting, densitometry, and caspase-3 ELISA.

Results

An increase of CSN subunits in response to MMC treatment was detected. Apoptosis was only measured after 4 h with 50 μM MMC. MMC-induced apoptosis was elevated by cotreatment with curcumin. Transfection of HT29 cells with let-7a-1 reduced the expression of tested CSN subunits associated with the accumulation of the pro-apoptotic factors p27 and p53.

Conclusions

In response to MMC treatment, the CSN is elevated as a regulator of DDR retarding apoptosis in tumor cells. The therapeutic effect of HIPEC can be increased by inhibiting CSN-associated kinases via curcumin or by blocking CSN expression with let-7a-1 miRNA.

Weber T, Roitman M, Link KH (2012) Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin Colorectal Cancer 11:167–176PubMedCrossRef

Turaga K, Levine E, Barone R et al. (2013) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol

Tsilimparis N, Bockelmann C, Raue W et al (2013) Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 20:226–232PubMedCrossRef

Raue W, Kilian M, Braumann C et al (2010) Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int J Colorectal Dis 25:245–250PubMedCrossRef

Spiliotis JD (2010) Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology 57:1173–1177PubMed

Bouquet W, Boterberg T, Ceelen W et al (2009) In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC. Int J Pharm 367:148–154PubMedCrossRef

Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242PubMedCrossRef

Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292PubMedCrossRef

Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 23:431–442PubMedCrossRef

10.

Tomasz M, Palom Y (1997) The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76:73–87PubMedCrossRef

11.

Hannss R, Dubiel W (2011) COP9 signalosome function in the DDR. FEBS Lett 585:2845–2852PubMedCrossRef

12.

Deng XW, Dubiel W, Wei N et al (2000) Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16:202–203PubMedCrossRef

13.

Schwechheimer C, Isono E (2010) The COP9 signalosome and its role in plant development. Eur J Cell Biol 89:157–162PubMedCrossRef

14.

Braus GH, Irniger S, Bayram O (2010) Fungal development and the COP9 signalosome. Curr Opin Microbiol 13:672–676PubMedCrossRef

15.

Kato JY, Yoneda-Kato N (2009) Mammalian COP9 signalosome. Genes Cells 14:1209–1225PubMedCrossRef

16.

Schmaler T, Dubiel W 2010 Control of deneddylation by the COP9 signalosome. Vol. 54. Austin, New York: Landes Bioscience and Springer Science + Business Media

17.

Seeger M, Kraft R, Ferrell K et al (1998) A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. Faseb J 12:469–478PubMed

18.

Cope GA, Suh GS, Aravind L et al (2002) Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298:608–611PubMedCrossRef

19.

Uhle S, Medalia O, Waldron R et al (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. Embo J 22:1302–1312PubMedCentralPubMedCrossRef

20.

Sun L, Shi L, Wang F et al (2010) Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization. J Biol Chem 286:4226–4235PubMedCentralPubMedCrossRef

21.

Huang X, Wagner E, Dumdey R et al (2006) Phosphorylation by COP9 signalosome-associated CK2 promotes degradation of p27 during the G1 cell cycle phase. Israel J Chem 46:231–238CrossRef

22.

Bech-Otschir D, Kraft R, Huang X et al (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. Embo J 20:1630–1639PubMedCentralPubMedCrossRef

23.

Fullbeck M, Huang X, Dumdey R et al (2005) Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 5:97PubMedCentralPubMedCrossRef

24.

Braumann C, Tangermann J, Jacobi CA et al (2008) Novel anti-angiogenic compounds for application in tumor therapy—COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem 8:421–428PubMedCrossRef

25.

Leppert U, Henke W, Huang X et al (2011) Post-transcriptional fine-tuning of COP9 signalosome subunit biosynthesis is regulated by the c-Myc/Lin28B/let-7 pathway. J Mol Biol 409:710–721PubMedCrossRef

26.

Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9–20PubMedCrossRef

27.

Saha A, Deshaies RJ (2008) Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 32:21–31PubMedCentralPubMedCrossRef

28.

Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434PubMedCrossRef

29.

Schmidt MW, McQuary PR, Wee S et al (2009) F-box-directed CRL complex assembly and regulation by the CSN and CAND1. Mol Cell 35:586–597PubMedCentralPubMedCrossRef

30.

Zemla A, Thomas Y, Kedziora S et al (2013) CSN- and CAND1-dependent remodelling of the budding yeast SCF complex. Nat Commun 4:1641PubMedCrossRef

31.

Groisman R, Polanowska J, Kuraoka I et al (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357–367PubMedCrossRef

32.

Dohmann EM, Levesque MP, De Veylder L et al (2008) The Arabidopsis COP9 signalosome is essential for G2 phase progression and genomic stability. Development 135:2013–2022PubMedCrossRef

33.

Beli P, Lukashchuk N, Wagner SA et al (2012) Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell 46:212–225PubMedCentralPubMedCrossRef

34.

Matsuoka S, Ballif BA, Smogorzewska A et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160–1166PubMedCrossRef

35.

González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2:68–75PubMedCentralPubMedCrossRef

36.

Weston CR, Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142–149PubMedCrossRef

37.

Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30:85–94PubMedCrossRef

38.

Sampson VB, Rong NH, Han J et al (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67:9762–9770PubMedCrossRef

39.

Francescutti V, Rivera L, Seshadri M et al (2013) The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 30:35–42PubMedCentralPubMed

40.

Pelz JO, Vetterlein M, Grimmig T et al (2013) Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 20:1105–1113PubMedCrossRef

41.

Fischer ES, Scrima A, Bohm K et al (2011) The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147:1024–1039PubMedCrossRef

42.

Echalier A, Pan Y, Birol M et al (2013) Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A 110:1273–1278PubMedCentralPubMedCrossRef

43.

Higa LA, Mihaylov IS, Banks DP et al (2003) Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 5:1008–1015PubMedCrossRef

44.

Sertic S, Evolvi C, Tumini E, et al. (2013) Non-canonical CRL4A/4B(CDT2) interacts with RAD18 to modulate post replication repair and cell survival. PLoS One 8:e60000

45.

Hoshino I, Matsubara H (2013) MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 43:467–478

46.

Nana-Sinkam SP, Croce CM (2013) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98–104PubMedCrossRef

Title: Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?
Authors: Mathilde Feist
Xiaohua Huang
Joachim M. Müller
Beate Rau
Wolfgang Dubiel
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 6/2014
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-014-1861-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

Effect of an elastic girdle on lung function, intra-abdominal pressure, and pain after midline laparotomy: a randomized controlled trial

Blue dye injection does not induce dissemination of epithelial cells during SLN procedure in colon cancer patients

Intestinal permeability, systemic endotoxemia, and bacterial translocation after open or laparoscopic resection: the critical role of bowel preparation

Rectal cancer only metastasis to the thyroid which has a primary papillary thyroid cancer

Predictive factors for perioperative blood transfusions in laparoscopic colorectal surgery

The use of purse-string skin closure in loop ileostomy reversals leads to lower wound infection rates—a single high-volume centre experience